Article
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Antiviral therapy - 1 Jan 2012
Sonneveld Milan J, Rijckborst Vincent, Cakaloglu Yilmaz, Simon Krzysztof, Heathcote E Jenny, Tabak Fehmi, Mach Tomasz, Boucher Charles A B, Hansen Bettina E, Zeuzem Stefan, Janssen Harry L A
Abstract excerpt
BACKGROUND: On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA<10,000 copies/ml at week 78), HBeAg responders (HBeAg loss with HBV DNA>10,000 copies/ml) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.